Kerecis Real-World Fish Skin Graft Registry
Launched by KERECIS LTD. · Apr 22, 2024
Trial Information
Current as of November 05, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a real-world, non-interventional registry called the Kerecis Real-World Fish Skin Graft Registry (ISACOD). It looks at how well the Kerecis Fish Skin Graft device works in everyday medical practice for various wounds—like diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and other soft-tissue wounds—over about a year. Because it’s observational, it does not assign treatments or change how care is given; instead, it collects information from patients who have already been treated with the device to understand safety and how wounds heal in real-life settings.
Who can be included? Any patient who gives informed consent, of any age or sex, and who has at least one wound treated with a Kerecis device within the month before enrollment. There are no listed exclusion criteria. The study plans to enroll about 600 people at multiple centers across the United States. Participants will have data collected during routine care for up to 12 months, focusing on whether the device causes problems or allergies, whether the wound gets infected, how long it takes to heal, and how often wounds completely close. The registry is sponsored by Kerecis Ltd., and results are not yet available.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provided informed consent
- • Has at least one target wound treated with a Kerecis device according to physician medical judgement within one calendar month prior to the registry enrollment date
- Exclusion Criteria:
- • None
About Kerecis Ltd.
Kerecis Ltd. is a pioneering biotechnology company focused on developing regenerative medicine solutions through the use of fish skin as a biologic alternative for wound healing and tissue regeneration. Leveraging advanced scientific research and innovative technology, Kerecis aims to address unmet medical needs in the treatment of chronic wounds, surgical wounds, and soft tissue reconstruction. The company's commitment to enhancing patient outcomes is reflected in its robust clinical trial programs, which are designed to validate the safety and efficacy of its products. By harnessing the natural properties of fish skin, Kerecis Ltd. is at the forefront of transforming wound care and improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sarasota, Florida, United States
Sarasota, Florida, United States
Greensboro, North Carolina, United States
Beavercreek, Ohio, United States
Columbus, Ohio, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Anne Swearingen
Principal Investigator
Kerecis Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported